Vitrolife — Board/Management Information 2012

Apr 18, 2012

Press release April 18, 2012 Gothenburg

Thomas Axelsson appointed CEO of Vitrolife

Vitrolife's Board has today appointed Thomas Axelsson as the new CEO of Vitrolife. Thomas has been working as the Acting CEO of the Group since November 2011.

Thomas Axelsson has broad experience and has displayed successful leadership and is the choice of the Board for the position of CEO after a thorough recruitment process where Thomas has competed with a number of other strong candidates. "Thomas has learnt about Vitrolife's business in a short period of time and established appreciated leadership. Thomas' broad experience from the medical device area will enrich the organization and we look forward to continuing our successful expansion under Thomas' leadership," says Patrik Tigerschiöld, Chairman of Vitrolife's Board.

"I have had the privilege of becoming acquainted with this successful company for a number of months now and look forward with great confidence to the opportunities that we see for continued expansive development. Vitrolife has an organization that runs smoothly, with very competent coworkers and together we will strengthen Vitrolife's global position", says Thomas Axelsson.

April 18, 2012 Gothenburg, Sweden VITROLIFE AB (publ) The Board

For further information, please contact: Patrik Tigerschiöld, Chairman of the Board, +46 8-614 00 22

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

______________________________________________________________________________________________________________________

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

___________________________________________________________________________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 18, 2012 at 2 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.